Neoadjuvant strategies for pancreatic cancer

doi:10.3748/wjg.v20.i28.9374

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 28

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5415)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-5) series.

Item

Count

PDF

378

WORD

172

HTML

2323

Tables (1-5)

613

Sum=3486

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

986

Download

943

Sum=1929

Jul 28, 2014 (publication date) through Feb 7, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Jul 28, 2014; 20(28): 9374-9383
Published online Jul 28, 2014. doi: 10.3748/wjg.v20.i28.9374

Table 3 Studies on neoadjuvant chemotherapy for locally advanced pancreatic cancer

Ref.	Study type	CT regimen	Staging system	LAPC (n)	Res rate (%)	R0 resections/total resections	ORR	OS median
Lee et al[51]	Prospective non-randomized	Gemcitabine + capecitabine	NCCNAPBCC	18 BR 25 UR33 BR 10 UR	61 BR 24 UR46 BR 20 UR	9/11 BR 5/6 UR13/15 BR 1/2 UR	NRNR	23.1 mo (cumulative)
Sahora et al[52]	Prospective phase II	NeoGEMTAX	NR	12 BR 13 UR	32	7/8	NR	16 mo (resected patients)
FARIS¹ et al[54]	Single centre, retrospective	FOLFIRINOX	NCNN	22	NR	22.7	27.3% (CT alone)	NR
Hosein¹ et al[39]	Prospective phase II	FOLFIRINOX	NR	14 BR 4UR	55.5	7/8	NR	16 mo (resected patients)

¹Some patients had CRT. ORR: Overall response rate; OS: Overall survival; NR: Not reported; NeoGEMTAX: Gemcitabine + docetaxel; FOLFIRINOX: 5-Fluorouracil + leucovorin + oxaliplatin + irinotecan; GEM: Gemcitabine; GEM FDR: Gemcitabine fixed dose ratio; NCCN: National comprehensive cancer network; APBCC: Asan pancreaticobiliary cancer center.

Citation: Polistina F, Natale GD, Bonciarelli G, Ambrosino G, Frego M. Neoadjuvant strategies for pancreatic cancer. World J Gastroenterol 2014; 20(28): 9374-9383
URL: https://www.wjgnet.com/1007-9327/full/v20/i28/9374.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i28.9374